Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy.
Kulsoom Bano MehdiSara AhmedSamrah RaziSafia AwanSyed Faisal MahmoodPublished in: BMC research notes (2019)
Mortality rate was 37% in those empirically treated with carbapenem compared to 20% treated with BL/BLI combination therapy (p-value: 0.012) and was 21% in those treated with a carbapenem compared to 13% in patients definitively treated with BL/BLI combination therapy (p-value: 0.152). In multivariable logistic regression analysis, only Pitt bacteremia score of ≥ four was significantly associated with mortality (OR: 7.7 CI 2.6-22.8) while a urinary source of bacteremia was protective (OR: 0.26 CI 0.11-0.58). In-hospital mortality in patients with Ceftriaxone resistant E. coli bacteremia did not differ in patients treated with either a carbapenem or BL/BLI combination. However, Pitt bacteremia score of ≥ 4 was strongly associated with mortality.
Keyphrases
- gram negative
- combination therapy
- multidrug resistant
- klebsiella pneumoniae
- acinetobacter baumannii
- cardiovascular events
- newly diagnosed
- escherichia coli
- end stage renal disease
- risk factors
- drug resistant
- ejection fraction
- chronic kidney disease
- cardiovascular disease
- type diabetes
- prognostic factors
- coronary artery disease
- peritoneal dialysis
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- smoking cessation
- data analysis